BACKGROUND: Mice lacking calsequestrin-1 (CASQ1-null), a Ca-binding protein that modulates the activity of Ca release in the skeletal muscle, exhibit lethal hypermetabolic episodes that resemble malignant hyperthermia in humans when exposed to halothane or heat stress. METHODS: Because oxidative species may play a critical role in malignant hyperthermia crises, we treated CASQ1-null mice with two antioxidants, N-acetylcysteine (NAC, Sigma-Aldrich, Italy; provided ad libitum in drinking water) and (±)-6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox, Sigma-Aldrich; administered by intraperitoneal injection), before exposure to halothane (2%, 1 h) or heat (41°C, 1 h). RESULTS: NAC and Trolox significantly protected CASQ1-null mice from lethal episodes, with mortality being 79% (n = 14), 25% (n = 16), and 20% (n = 5) during halothane exposure and 86% (n = 21), 29% (n = 21), and 33% (n = 6) during heat stress in untreated, NAC-treated, and Trolox-treated mice, respectively. During heat challenge, an increase in core temperature in CASQ1-null mice (42.3° ± 0.1°C, n=10) was significantly reduced by both NAC and Trolox (40.6° ± 0.3°C, n = 6 and 40.5° ± 0.2°C, n = 6). NAC treatment of CASQ1-null muscles/mice normalized caffeine sensitivity during in vitro contracture tests, Ca transients in single fibers, and significantly reduced the percentage of fibers undergoing rhabdomyolysis (37.6 ± 2.5%, 38/101 fibers in 3 mice; 11.6 ± 1.1%, 21/186 fibers in 5 mice). The protective effect of antioxidant treatment likely resulted from mitigation of oxidative stress, because NAC reduced mitochondrial superoxide production, superoxide dismutase type-1 expression, and 3-nitrotyrosine expression, and increased both reduced glutathione and reduced glutathione/oxidized glutathione ratio. CONCLUSION: These studies provide a deeper understanding of the mechanisms that underlie hyperthermic crises in CASQ1-deficient muscle and demonstrate that antioxidant pretreatment may prevent them.
BACKGROUND: Mice lacking calsequestrin-1 (CASQ1-null), a Ca-binding protein that modulates the activity of Ca release in the skeletal muscle, exhibit lethal hypermetabolic episodes that resemble malignant hyperthermia in humans when exposed to halothane or heat stress. METHODS: Because oxidative species may play a critical role in malignant hyperthermia crises, we treated CASQ1-null mice with two antioxidants, N-acetylcysteine (NAC, Sigma-Aldrich, Italy; provided ad libitum in drinking water) and (±)-6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox, Sigma-Aldrich; administered by intraperitoneal injection), before exposure to halothane (2%, 1 h) or heat (41°C, 1 h). RESULTS: NAC and Trolox significantly protected CASQ1-null mice from lethal episodes, with mortality being 79% (n = 14), 25% (n = 16), and 20% (n = 5) during halothane exposure and 86% (n = 21), 29% (n = 21), and 33% (n = 6) during heat stress in untreated, NAC-treated, and Trolox-treated mice, respectively. During heat challenge, an increase in core temperature in CASQ1-null mice (42.3° ± 0.1°C, n=10) was significantly reduced by both NAC and Trolox (40.6° ± 0.3°C, n = 6 and 40.5° ± 0.2°C, n = 6). NAC treatment of CASQ1-null muscles/mice normalized caffeine sensitivity during in vitro contracture tests, Ca transients in single fibers, and significantly reduced the percentage of fibers undergoing rhabdomyolysis (37.6 ± 2.5%, 38/101 fibers in 3 mice; 11.6 ± 1.1%, 21/186 fibers in 5 mice). The protective effect of antioxidant treatment likely resulted from mitigation of oxidative stress, because NAC reduced mitochondrial superoxide production, superoxide dismutase type-1 expression, and 3-nitrotyrosine expression, and increased both reduced glutathione and reduced glutathione/oxidized glutathione ratio. CONCLUSION: These studies provide a deeper understanding of the mechanisms that underlie hyperthermic crises in CASQ1-deficient muscle and demonstrate that antioxidant pretreatment may prevent them.
Authors: Lan Wei; Gheorghe Salahura; Simona Boncompagni; Karl A Kasischke; Feliciano Protasi; Shey-Shing Sheu; Robert T Dirksen Journal: FASEB J Date: 2011-06-06 Impact factor: 5.191
Authors: Mihail G Chelu; Sanjeewa A Goonasekera; William J Durham; Wei Tang; John D Lueck; Joyce Riehl; Isaac N Pessah; Pumin Zhang; Meenakshi B Bhattacharjee; Robert T Dirksen; Susan L Hamilton Journal: FASEB J Date: 2005-11-11 Impact factor: 5.191
Authors: William J Durham; Paula Aracena-Parks; Cheng Long; Ann E Rossi; Sanjeewa A Goonasekera; Simona Boncompagni; Daniel L Galvan; Charles P Gilman; Mariah R Baker; Natalia Shirokova; Feliciano Protasi; Robert Dirksen; Susan L Hamilton Journal: Cell Date: 2008-04-04 Impact factor: 41.582
Authors: M Davis; R Brown; A Dickson; H Horton; D James; N Laing; R Marston; M Norgate; D Perlman; N Pollock; K Stowell Journal: Br J Anaesth Date: 2002-04 Impact factor: 9.166
Authors: Johanna T Lanner; Dimitra K Georgiou; Adan Dagnino-Acosta; Alina Ainbinder; Qing Cheng; Aditya D Joshi; Zanwen Chen; Viktor Yarotskyy; Joshua M Oakes; Chang Seok Lee; Tanner O Monroe; Arturo Santillan; Keke Dong; Laurie Goodyear; Iskander I Ismailov; George G Rodney; Robert T Dirksen; Susan L Hamilton Journal: Nat Med Date: 2012-01-08 Impact factor: 53.440
Authors: Danielle Carpenter; Christopher Ringrose; Vincenzo Leo; Andrew Morris; Rachel L Robinson; P Jane Halsall; Philip M Hopkins; Marie-Anne Shaw Journal: BMC Med Genet Date: 2009-10-13 Impact factor: 2.103
Authors: Laura Pietrangelo; Alessandra D'Incecco; Alina Ainbinder; Antonio Michelucci; Helmut Kern; Robert T Dirksen; Simona Boncompagni; Feliciano Protasi Journal: Oncotarget Date: 2015-11-03
Authors: Simona Boncompagni; Antonio Michelucci; Laura Pietrangelo; Robert T Dirksen; Feliciano Protasi Journal: Sci Rep Date: 2017-10-27 Impact factor: 4.379